查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094235

骨關節炎治療市場－2026-2032年全球市場預測

Osteoarthritis Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨關節炎治療市場規模將成長至 93.5 億美元，複合年成長率為 7.72%。

主要市場統計數據
基準年 2025 55.5億美元
預計年份：2026年 59.7億美元
預測年份 2032 93.5億美元
複合年成長率 (%) 7.72%

執行摘要治療藥物摘要

骨關節炎的治療正從單純的緩解症狀轉向綜合疾病管理，結合藥物治療、注射治療、數位監測、復健治療、體重管理以及避免手術的護理路徑。骨關節炎是全球最常見的關節炎類型，也是導致殘疾的主要原因之一，尤其是在老年人、肥胖者、有關節損傷史者、長期承受重複性職業壓力者或肌肉無力者中更為常見。目前的治療方法包括口服和外用非類固醇消炎劑、對某些患者使用對乙醯胺酚、關節內注射皮質類固醇、在特定情況下使用透明質酸、物理治療、輔助器具、矯正器具以及生活方式的改變，只有在關節損傷嚴重或功能嚴重受限的情況下才會考慮手術治療。

一項變革性的改變，將重塑骨關節炎的治療方式。

骨關節炎的治療格局正在經歷一場變革，其驅動力包括人口結構變化、科學進步以及保險公司、臨床醫生和患者不斷變化的期望。首要的轉變是從一般疼痛管理轉向以表現型為基礎的治療。人們越來越認知到，骨關節炎是一種高度異質性的疾病，涉及發炎、代謝、機械、骨骼相關因素以及痛覺過敏路徑。這正在加速標靶療法的研發，並推動臨床試驗中更精準的患者篩選。

人工智慧對骨關節炎治療的累積影響

人工智慧 (AI) 透過改善診斷、臨床試驗設計、個人化治療和治療後監測，對骨關節炎的整體治療產生了累積的影響。在診斷領域，AI 驅動的影像分析可以輔助評估關節間隙狹窄、軟骨缺失、骨贅、骨髓病變、滑膜炎模式以及關節排列變化等情況，這些評估可利用 X 光、MRI 和其他影像技術。經臨床標準檢驗後，這些工具可以幫助早期識別結構進展，並減少 X 光影像解讀的差異。

關於骨關節炎治療的關鍵區域見解

在亞太地區，骨關節炎治療的需求與人口老化、都市區生活方式的改變、多個國家肥胖率的上升以及專科醫療服務的可近性提高密切相關。日本和韓國在整形外科和風濕病領域擁有完善的基礎設施，而中國、印度、澳洲和東南亞市場正在經歷診斷、品牌學名藥、注射、物理治療以及基於數位健康的慢性病管理等服務的日益普及。保險報銷和自付費用的差異仍然影響著治療選擇，經濟負擔會影響局部非類固醇抗發炎藥物、口服止痛藥、關節內治療和復健服務的使用。

影響骨關節炎治療的關鍵群體特定見解

在東協地區，骨關節炎的治療趨勢正受到多個成員國人口快速老化、都市區醫療保健服務覆蓋範圍擴大以及對經濟實惠的口服和外用鎮痛藥的高度依賴等因素的影響。雖然主要城市復健服務和關節內治療的普及程度正在提高，但農村地區醫療資源獲取方面的差距仍然推動著人們對價格合理的一線療法和基層醫療為基礎的疼痛管理的需求。

骨關節炎治療的關鍵國家見解

由於診斷數量眾多、臨床指引廣泛應用、高度重視疼痛管理以盡量減少鴉片類藥物的使用，以及保險公司注重治療效果和醫療資源利用管理等因素，美國已成為骨關節炎治療的核心市場。加拿大同樣重視實證處方、保守治療、復健和公平的醫療服務獲取，但各省的健保報銷制度差異可能會影響治療的可近性。墨西哥的骨關節炎治療格局則受到公共和私人醫療保健體系分散、對價格合理的鎮痛藥需求旺盛以及都市區專科醫療服務可及性提高等因素的影響。

為骨關節炎治療領域的領導者提供的實用建議

產業領導者應優先研發差異化的骨關節炎治療方案，以滿足已證實的未滿足需求，即持續緩解疼痛、改善功能、減少全身不利事件，以及在明確定義的患者亞群中證實療效。研發策略應從早期階段納入以表現型為基礎的臨床試驗受試者選擇、影像學和生化標記、病患報告結局（HRQOL）、功能終點以及真實世界資料（RWE）收集計畫。

調查方法

本執行摘要採用系統的二手資料研究方法編寫，所用資料均來自公開可查的來源，包括臨床實踐指南、監管出版刊物、同行檢驗的醫學文獻、流行病學研究、衛生部門資訊來源以及經認證的公共衛生和專業機構發布的肌肉骨骼疾病報告。分析重點在於骨關節炎治療相關的治療路徑、治療創新、區域可近性趨勢、疾病負擔指標、監管考慮、安全訊號和技術應用研究途徑。

結論

骨關節炎的治療正進入一個更個人化、循證且以數位技術為支撐的發展和應用階段。該領域正從廣泛的症狀治療轉向以緩解疼痛、恢復身體功能、確保安全、進行患者分層和長期活動能力為優先的綜合護理。隨著人口老化、肥胖、創傷相關關節退化以及減少殘疾的需求，骨關節炎將繼續成為全球重大的醫療保健挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 骨關節炎治療市場：依治療類型分類

  • 輔助療法
    • 針刺
    • 按摩療法
    • 營養補充品
  • 藥物治療
    • 皮質類固醇注射
    • 玻尿酸注射
    • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物
  • 物理治療
  • 外科手術
    • 關節鏡
    • 關節重建手術
    • 截骨術
      • 股骨截骨術
      • 脛骨截骨術

第8章：骨關節炎治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用
  • 經皮給藥

第9章 骨關節炎治療市場：依最終用戶分類

  • 診所
  • 醫院
  • 復健中心

第10章：骨關節炎治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 骨關節炎治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 骨關節炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 骨關節炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Anika Therapeutics, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Doron Therapeutics
  • Eli Lilly and Company
  • Endo International plc
  • Ferring BV
  • Fidia Farmaceutici SpA
  • GSK PLC
  • Hanmi Pharm. Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services Inc.
  • Kitov Pharmaceuticals Ltd.
  • Mankind Pharma
  • Merck & Co.
  • Pacira BioSciences, Inc.
  • Par Health
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-DD6333AE50BA

The Osteoarthritis Therapeutics Market is projected to grow by USD 9.35 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.55 billion
Estimated Year [2026] USD 5.97 billion
Forecast Year [2032] USD 9.35 billion
CAGR (%) 7.72%

Osteoarthritis Therapeutics Executive Summary

Osteoarthritis therapeutics are moving beyond symptomatic pain relief toward integrated disease management that combines pharmacologic treatment, injectables, digital monitoring, rehabilitation, weight management, and procedure-sparing care pathways. Osteoarthritis is the most common form of arthritis globally and a leading contributor to disability, particularly among aging populations and people with obesity, prior joint injury, repetitive occupational loading, or reduced muscle strength. Current treatment approaches include oral and topical nonsteroidal anti-inflammatory drugs, acetaminophen in selected patients, intra-articular corticosteroids, hyaluronic acid in selected settings, physical therapy, assistive devices, bracing, and lifestyle interventions, with surgical referral reserved for advanced joint damage and severe functional limitation.

The therapeutic landscape is shaped by a persistent unmet need: patients require durable pain control, improved mobility, fewer systemic adverse events, and interventions that may slow structural progression rather than only mask symptoms. Regulatory agencies and clinical societies continue to emphasize evidence-based prescribing, patient phenotyping, opioid-sparing strategies, weight management, structured exercise, and shared decision-making. As a result, industry participants are focusing on safer analgesics, locally delivered therapies, regenerative and biologic approaches, companion diagnostics, real-world evidence, and digital tools that support adherence and long-term outcomes in knee, hip, hand, and spine osteoarthritis.

Transformative Shifts Reshaping Osteoarthritis Therapeutics

The osteoarthritis therapeutics landscape is undergoing transformative shifts driven by demographic pressure, scientific advances, and changing expectations from payers, clinicians, and patients. The first major shift is the transition from generalized pain management to phenotype-guided treatment. Osteoarthritis is increasingly understood as a heterogeneous disease involving inflammatory, metabolic, mechanical, bone-driven, and pain-sensitization pathways. This is encouraging development of targeted interventions and more precise patient selection in clinical trials.

A second shift is the move toward opioid-sparing and steroid-sparing care. Public health concerns related to opioid dependence and long-term safety concerns around repeated corticosteroid exposure have strengthened demand for topical therapies, non-opioid analgesics, physical therapy integration, and minimally invasive intra-articular options. Clinical practice has also placed greater emphasis on nonpharmacologic interventions such as structured exercise, weight reduction, bracing, patient education, and self-management programs.

A third shift is the growing importance of real-world evidence and patient-reported outcomes. Regulators, health technology assessors, and payers increasingly expect evidence on pain reduction, physical function, quality of life, durability of response, rescue medication use, safety, and healthcare utilization. Digital endpoints, wearable activity data, imaging biomarkers, and longitudinal registries are becoming more relevant as stakeholders seek to understand treatment performance outside controlled trial environments.

Finally, innovation is expanding from single-agent therapy to multimodal musculoskeletal care. Digital therapeutics, remote physiotherapy, AI-assisted imaging, biomarker-driven trial enrollment, and integrated orthopedic-rheumatology pathways are changing how osteoarthritis is diagnosed, monitored, and treated across the patient journey.

Cumulative Impact of Artificial Intelligence on Osteoarthritis Care

Artificial intelligence is becoming a cumulative force across osteoarthritis therapeutics by improving diagnosis, clinical trial design, treatment personalization, and post-treatment monitoring. In diagnostics, AI-enabled imaging analysis can support the assessment of joint space narrowing, cartilage loss, osteophytes, bone marrow lesions, synovitis patterns, and alignment changes on X-ray, MRI, and other imaging modalities. These tools can help identify structural progression earlier and reduce variability in radiographic interpretation when validated against clinical standards.

In drug development, machine learning is being applied to patient stratification, biomarker discovery, trial eligibility screening, and prediction of response to investigational therapies. Because osteoarthritis progresses slowly and displays substantial clinical heterogeneity, AI can help identify subgroups with inflammatory activity, rapid structural progression, metabolic risk factors, or centralized pain features, enabling more efficient study designs and more clinically meaningful endpoints.

AI also supports real-world care delivery. Predictive models can identify patients at risk of worsening pain, reduced mobility, falls, work impairment, or future joint replacement referral. Digital platforms using wearable sensors and smartphone-based assessments can track gait, activity, sleep, medication adherence, and rehabilitation engagement. For clinicians, this can improve follow-up timing and therapeutic adjustment; for payers, it can support value-based care; and for patients, it can enable earlier intervention and better self-management.

However, AI adoption requires validated algorithms, representative datasets, explainability, privacy safeguards, and integration into clinical workflows. Bias in imaging datasets, inconsistent data standards, and uncertain reimbursement for AI-enabled musculoskeletal tools remain barriers. The strongest near-term value lies in AI systems that complement clinical judgment, improve operational efficiency, and generate evidence for measurable improvements in pain, function, and care continuity.

Key Regional Insights Across Osteoarthritis Therapeutics

In Asia-Pacific, osteoarthritis therapeutics demand is closely linked to population aging, urban lifestyle changes, rising obesity rates in several countries, and improved access to specialty care. Japan and South Korea have advanced orthopedic and rheumatology infrastructure, while China, India, Australia, and Southeast Asian markets are expanding access to diagnostics, branded generics, injectables, physiotherapy, and digital health-enabled chronic disease management. Variability in reimbursement and out-of-pocket spending continues to influence treatment selection, with affordability shaping the use of topical NSAIDs, oral analgesics, intra-articular therapies, and rehabilitation services.

North America remains a highly evidence-driven region for osteoarthritis treatment, supported by broad clinical guideline adoption, established payer scrutiny, extensive use of real-world evidence, and strong demand for opioid-sparing pain management. The United States and Canada emphasize multidisciplinary care, physical therapy, weight management, assistive technologies, and careful pharmacologic selection due to concerns about cardiovascular, gastrointestinal, renal, and dependency-related risks associated with some therapies.

Latin America is characterized by a high burden of musculoskeletal disability, expanding access to generic medicines, and uneven availability of specialist services across urban and rural settings. Brazil and Mexico play important roles in regional treatment adoption, with demand shaped by public healthcare capacity, private insurance coverage, workforce constraints, and the need for cost-effective pain management and mobility-preserving interventions.

Europe demonstrates strong alignment with evidence-based clinical practice, pharmacovigilance, and health technology assessment. Countries across the region prioritize conservative care, topical NSAIDs where appropriate, structured exercise, patient education, and cautious use of intra-articular interventions based on clinical guidance. Reimbursement frameworks and national health systems influence access to innovative therapies, digital musculoskeletal programs, advanced imaging, and rehabilitation services.

The Middle East is seeing rising osteoarthritis burden associated with demographic change, obesity, sedentary lifestyles, and increased diagnosis of chronic musculoskeletal conditions. Gulf countries are investing in specialty care infrastructure, rehabilitation services, and digital health, while access patterns vary across the wider region. In Africa, osteoarthritis care is affected by limited specialist availability, variable diagnostic access, and affordability constraints, but the need for low-cost analgesics, community-based rehabilitation, and scalable mobility interventions is significant as aging and noncommunicable disease burdens increase.

Key Group Insights Influencing Osteoarthritis Therapeutics

Across ASEAN, osteoarthritis therapeutics are shaped by rapid population aging in several member states, growing urban healthcare access, and strong reliance on cost-effective oral and topical pain therapies. Rehabilitation services and intra-articular treatment availability are expanding in major cities, while rural access gaps sustain demand for affordable first-line therapies and primary care-based disease management.

The GCC is positioned around high healthcare investment, rising obesity prevalence, and increasing attention to chronic musculoskeletal conditions that affect productivity and quality of life. Care models in the region are moving toward specialist-led orthopedic and rheumatology services, medical tourism integration in selected locations, preventive health programs, and digital health adoption, creating opportunities for therapies and platforms that support long-term mobility management.

The European Union is defined by regulatory rigor, pharmacovigilance, clinical guideline adherence, and health technology assessment. Treatment adoption depends heavily on demonstrated clinical benefit, safety, cost-effectiveness, and compatibility with national reimbursement systems. EU-wide emphasis on healthy aging, workplace participation, and reduced surgical burden supports interest in preventive care, structured exercise, rehabilitation, and evidence-backed non-opioid interventions.

BRICS countries represent diverse but high-need osteoarthritis environments, combining large patient populations, expanding middle-class healthcare demand, and growing domestic capabilities in generics, biosciences, diagnostics, and digital health. China and India are especially important due to scale and rising chronic disease management needs, while Brazil, Russia, and South Africa face varied access, reimbursement, and infrastructure challenges that shape uptake of advanced osteoarthritis therapeutics.

The G7 group reflects mature healthcare systems where osteoarthritis therapeutics are evaluated through robust clinical evidence, payer controls, safety monitoring, and patient-centered outcomes. Aging demographics, high joint replacement utilization, and pressure to reduce long-term disability support continued demand for therapies that delay functional decline. NATO countries, overlapping substantially with North America and Europe, show strong emphasis on workforce readiness, rehabilitation, and musculoskeletal health among aging civilian and veteran populations, making mobility preservation and non-opioid pain management key priorities.

Key Country Insights for Osteoarthritis Therapeutics

The United States is a central environment for osteoarthritis therapeutics due to its high diagnosed burden, extensive use of clinical guidelines, strong focus on opioid-sparing pain care, and payer emphasis on outcomes and utilization management. Canada similarly prioritizes evidence-based prescribing, conservative management, rehabilitation, and equitable access, although provincial reimbursement variation can affect therapy availability. Mexico's osteoarthritis treatment environment is shaped by public-private healthcare segmentation, high demand for affordable analgesics, and improving access to specialist care in urban centers.

Brazil has a substantial musculoskeletal disease burden and growing demand for cost-effective therapies, rehabilitation, and injectable options, while broader access depends on public system capacity and private coverage. The United Kingdom emphasizes guideline-led management, exercise, weight management, topical NSAIDs, and careful selection of pharmacologic therapy within a publicly funded care model. Germany combines strong specialist care, rehabilitation infrastructure, and rigorous assessment of therapeutic value, supporting adoption where safety and functional benefit are clearly demonstrated. France maintains a structured healthcare environment with attention to reimbursement evidence and appropriate use of symptomatic therapies. Russia faces a large need for osteoarthritis management across a geographically broad population, with access varying by region and healthcare setting. Italy and Spain have aging populations and established rheumatology and orthopedic services, with ongoing pressure to manage chronic pain, preserve function, and limit unnecessary surgical escalation.

China is experiencing rising osteoarthritis diagnosis linked to aging, urbanization, obesity trends, and improved access to imaging and specialty care, creating demand for scalable pharmacologic, injectable, rehabilitation, and digital care options. India faces a large and growing osteoarthritis burden, particularly knee osteoarthritis, with treatment strongly influenced by affordability, generic medicine access, urban specialist availability, and increasing awareness of lifestyle-based management. Japan's super-aged population creates sustained need for mobility-preserving therapies, rehabilitation, fall-risk reduction, and safe long-term pain management. Australia emphasizes evidence-based musculoskeletal care, physiotherapy, weight reduction, and careful prescribing in line with national guidance. South Korea combines advanced healthcare infrastructure, strong diagnostic access, and growing digital health integration, supporting continued evolution toward personalized and monitored osteoarthritis management.

Actionable Recommendations for Osteoarthritis Therapeutics Leaders

Industry leaders should prioritize differentiated osteoarthritis therapeutics that address validated unmet needs: durable pain relief, functional improvement, reduced systemic adverse events, and evidence of benefit in clearly defined patient subgroups. Development strategies should incorporate phenotype-based trial enrollment, imaging and biochemical biomarkers, patient-reported outcomes, functional endpoints, and real-world evidence plans from the earliest stages.

Organizations should also invest in integrated care models that combine therapeutics with rehabilitation, digital adherence tools, remote monitoring, weight management, and lifestyle support. Partnerships with clinicians, payers, digital health providers, and rehabilitation networks can strengthen patient engagement and demonstrate practical value beyond symptom reduction. Given increasing scrutiny of opioids, repeated corticosteroid use, and broad systemic analgesic exposure, positioning around safety, opioid-sparing pathways, and function-first outcomes is essential.

For commercialization, stakeholders should tailor access strategies to regional healthcare realities. Mature healthcare systems require comparative evidence, pharmacoeconomic support, safety monitoring, and guideline alignment, while emerging markets require affordability, education, distribution reach, and scalable primary care integration. Organizations should prepare for stronger demand for transparency, post-market safety surveillance, and evidence that therapies reduce disability, improve daily activity, and support long-term musculoskeletal health.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available, verifiable sources, including clinical practice guidelines, regulatory publications, peer-reviewed medical literature, epidemiological studies, health authority documents, and musculoskeletal disease reports from recognized public health and professional bodies. The analysis focuses on treatment pathways, therapeutic innovation, regional access dynamics, disease burden indicators, regulatory considerations, safety signals, and technology adoption trends relevant to osteoarthritis therapeutics.

The methodology emphasizes triangulation of evidence across clinical, regulatory, and healthcare delivery sources to identify consistent patterns while avoiding unsupported claims. Insights are qualitatively assessed across regions, economic groups, and key countries based on healthcare infrastructure, reimbursement environment, demographic trends, clinical practice norms, and adoption of pharmacologic, injectable, rehabilitative, and digital musculoskeletal interventions. No market sizing, market share estimation, or forecasting is included.

Conclusion

Osteoarthritis therapeutics are entering a more personalized, evidence-driven, and digitally supported phase of development and delivery. The field is shifting from broad symptomatic treatment toward integrated care that prioritizes pain relief, physical function, safety, patient stratification, and long-term mobility. Aging populations, obesity, injury-related joint degeneration, and the need to reduce disability will continue to place osteoarthritis high on healthcare agendas worldwide.

The most successful strategies will be those that combine scientific differentiation with practical access, clinician trust, patient engagement, and measurable real-world outcomes. AI-enabled diagnostics, phenotype-guided treatment development, safer non-opioid therapies, and multimodal care platforms are expected to play an increasingly important role. For stakeholders across the osteoarthritis therapeutics ecosystem, the strategic priority is clear: deliver therapies and care models that improve mobility, reduce chronic pain burden, preserve function, and fit the economic and clinical realities of diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Osteoarthritis Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Complementary Therapies
    • 7.2.1. Acupuncture
    • 7.2.2. Massage Therapy
    • 7.2.3. Nutritional Supplements
  • 7.3. Drug Therapy
    • 7.3.1. Corticosteroid Injections
    • 7.3.2. Hyaluronic Acid Injections
    • 7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.3.4. Opioids
  • 7.4. Physical Therapy
  • 7.5. Surgery
    • 7.5.1. Arthroscopy
    • 7.5.2. Joint Replacement
    • 7.5.3. Osteotomy
      • 7.5.3.1. Femoral Osteotomy
      • 7.5.3.2. Tibial Osteotomy

8. Osteoarthritis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical
  • 8.5. Transdermal

9. Osteoarthritis Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals
  • 9.4. Rehabilitation Centers

10. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Osteoarthritis Therapeutics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Osteoarthritis Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Osteoarthritis Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Amgen Inc.
  • 15.3. Anika Therapeutics, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Bayer AG
  • 15.6. Boehringer Ingelheim International GmbH
  • 15.7. Cipla Ltd.
  • 15.8. Doron Therapeutics
  • 15.9. Eli Lilly and Company
  • 15.10. Endo International plc
  • 15.11. Ferring B.V.
  • 15.12. Fidia Farmaceutici S.p.A
  • 15.13. GSK PLC
  • 15.14. Hanmi Pharm. Co., Ltd.
  • 15.15. Hikma Pharmaceuticals PLC
  • 15.16. Johnson & Johnson Services Inc.
  • 15.17. Kitov Pharmaceuticals Ltd.
  • 15.18. Mankind Pharma
  • 15.19. Merck & Co.
  • 15.20. Pacira BioSciences, Inc.
  • 15.21. Par Health
  • 15.22. Pfizer Inc.
  • 15.23. Sanofi S.A.
  • 15.24. Sun Pharmaceutical Industries Ltd.
  • 15.25. Takeda Pharmaceutical Company
  • 15.26. Teva Pharmaceutical Industries Ltd.
  • 15.27. UCB S.A.
  • 15.28. Viatris Inc.
  • 15.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUPUNCTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUPUNCTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUPUNCTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MASSAGE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MASSAGE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MASSAGE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUTRITIONAL SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUTRITIONAL SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUTRITIONAL SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROID INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROID INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORTICOSTEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYALURONIC ACID INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYALURONIC ACID INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYALURONIC ACID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTHROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTHROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTHROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JOINT REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JOINT REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JOINT REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEMORAL OSTEOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMORAL OSTEOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEMORAL OSTEOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TIBIAL OSTEOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TIBIAL OSTEOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TIBIAL OSTEOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 182. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 331. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 332. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025